Revenue Recognition (Details) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2023 USD ($) $ / shares	Jun. 30, 2022 USD ($) $ / shares	Jun. 30, 2023 USD ($) item $ / shares	Jun. 30, 2022 USD ($) $ / shares	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Aug. 31, 2019 USD ($)	Jun. 30, 2019 USD ($)
Deferred revenue, Long-term	$ 21,502		$ 21,502		$ 20,001
Increased (decreased) revenues	3,400	$ 4,200	(5,800)	$ 10,600
(Increased) decreased net loss	$ 3,400	$ 4,200	$ (5,800)	$ 10,600
(Increased) decreased net loss per share | $ / shares	$ 0.03	$ 0.04	$ (0.05)	$ 0.11
Other assets	$ 17,518		$ 17,518		18,330
Deferred revenue	37,146	$ 36,730	37,146	$ 36,730	30,778	$ 28,722
Deferred revenue, current portion	15,644		15,644		10,777
Total revenues	261,404	198,200	503,160	392,333
Deferred revenue, long-term portion	21,502		21,502		20,001
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			7,521	5,757
Product
Revenue recognized			6,500	2,500
Cost of revenues	142,808	108,756	$ 290,562	$ 211,426
Billing collection period (in months)			18 months
Increased (decreased) revenues	800	1,100
(Increased) decreased net loss	$ 800	$ 1,100
(Increased) decreased net loss per share | $ / shares	$ 0.01	$ 0.01	$ 0.06	$ 0.03
Total revenues	$ 258,256	$ 194,582	$ 496,053	$ 384,584
Licensing and other
Cost of revenues	341	481	711	1,026
Total revenues	3,148	$ 3,618	7,107	7,749
Genetic testing services
Deferred revenue, current portion	13,400		13,400
Revenue recognized during the period that was included in deferred revenues at the beginning of the period			$ 7,200
Laboratory distribution partners | Product | Minimum
Billing collection period (in months)			2 months
Laboratory distribution partners | Product | Maximum
Billing collection period (in months)			3 months
BGI Genomics
Revenue recognized			$ 44,000
Agreement term			10 years
Revenue, remaining performance obligation	6,000		$ 6,000
Deferred revenue, Long-term	19,800		19,800
Initial transaction price	50,000		50,000
Prepaid expenses and other current assets					4,000
Deferred revenue	19,800		19,800
Prepaid royalties	20,000		20,000
Deferred revenue, long-term portion	19,800		19,800
BGI Genomics | License and related development services
Revenue recognized			$ 100	2,700
Number of performance obligations | item			2
Revenue, remaining performance obligation	24,000		$ 24,000
BGI Genomics | Sequencing services
Other assets	7,300		7,300					$ 6,000
Equipment and services received	1,000
BGI Genomics | Sequencing products
Other assets								4,000
Prepaid expenses and other current assets	2,200		2,200
Equipment and services received			2,600
BGI Genomics | Sequencing products and services
Other assets	5,100		5,100					$ 10,000
BGI Genomics | Oncology assay interpretation services
Revenue recognized			600
BGI Genomics | Royalty
Revenue recognized			$ 200		$ 0
Number of performance obligations | item			2
Revenue, remaining performance obligation	20,000		$ 20,000
Foundation Medicine ("FMI")
Revenue recognized			$ 24,300
Agreement term			5 years
Automatic renewals, successive period thereafter			1 year
Revenue, remaining performance obligation	7,700		$ 7,700
Deferred revenue, Long-term	1,700		1,700
Initial transaction price							$ 32,000
Deferred revenue	4,000		4,000
Deferred revenue, current portion	2,300		2,300
Prepaid royalties	5,000		5,000
Deferred revenue, long-term portion	1,700		1,700
Foundation Medicine ("FMI") | Oncology assay interpretation services
Revenue recognized			400	100
Revenue, remaining performance obligation	5,000		5,000
Foundation Medicine ("FMI") | Oncology products
Revenue recognized			200	$ 1,100
Revenue, remaining performance obligation	$ 19,300		$ 19,300